三门峡狐臭要如何治疗三门峡治疗女孩腋臭的方法,三门峡治疗狐臭最好时间,三门峡狐臭治有几种方式,三门峡痘痘治疗好,三门峡开水烫伤疤痕修复,三门峡治腋臭什么方法最好,三门峡皮炎治疗费用

BEIJING, July 27 (Xinhuanet) -- Amazon.com’s e-book reader Kindle 3G with special offers is now the company’s top-selling e-book device, according to media reports on Wednesday.Amazon revealed in its quarterly earnings report that the ad-supported version costs 139 U.S. dollars,  50 dollars cheaper than the comparable Kindle 3G, and costs the same as a Kindle with Wi-Fi connectivity. Many believe Kindle is the most popular dedicated e-book device on the market today.The advertisements will appear only in screensavers (which appear when the reader is in an idle state) and at the bottom of the home screen, so they don’t interrupt readers.“Since AT&T agreed to sponsor screensavers, Kindle 3G with Special Offers is now our bestselling Kindle device,” Amazon’s press release said.Having zoomed past the earlier Sony Reader, and kicked off a wave of competition including the Barnes & Noble Nook and the Kobo E-Reader, Kindle is believed the most popular dedicated e-book device on the market today.

BEIJING, Aug. 30 (Xinhuanet) -- The search giant Google admits it sees the new Google+ social network as an "identity service" or platform on which it can build other products, according to media reports.Google chariman Eric Schmidt said Google isn't interested in changing its policies to accommodate users such as political dissidents or others who prefer to remain anonymous: If people want to remain anonymous, then they shouldn't use Google+."Fundamentally, [Google+] depends on people using their real names if they're going to build future products that leverage that information," NPR's Andy Carvin wrote in a post on Google+ as he paraphrased Schmidt's remarks.Critics say the move is harmful to political activists, victims of harassment and numerous other groups for whom using a real name online might pose a safety risk, according to CNN reports."Regarding people who are concerned about their safety, [Schmidt] said G+ is completely optional," Carvin wrote.Meanwhile, according to Carvin, Schmidt also said "the Internet would be better if we knew you were a real person rather than a dog or a fake person. Some people are just evil and we should be able to ID them and rank them downward."

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Sept. 5 (Xinhua) -- China and the World Bank are jointly researching ways to help rebalance the world's second largest economy and move toward a path of sustainable growth under the current challenging global economic situation, said World Bank Group President Robert B. Zoellick on Monday.A report, jointly being prepared by the World Bank, China's Ministry of Finance, and the Development Research Center of the State Council, will be released later this year to support China in identifying the many challenges and policy choices it will face in the next two decades, as the country seeks to avoid the so-called "middle-income trap," a stage of economic development that has slowed progress in many countries, Zoellick said.Regarding this autumn as "a sensitive time facing the world's major economies," Zoellick said many countries, including the United States, the European Union and Japan, were facing the similar fundamental challenge of restructuring for sustainable economic growth."Perhaps the challenge is more difficult for China as the country has already made remarkable progress, and thus it's not easy to persuade people to make a change," he said.Commenting in Beijing on a weekend workshop with senior Chinese officials and outside experts, Zoellick said there was agreement that China will have to rebalance its economy, improve the environment, reduce inequality and advance the quality of life for its people while at the same time maintaining rapid growth."In the near term, inflation is China's priority, as Premier Wen Jiabao mentioned," Zoellick said, adding that the Chinese government was moving in the right direction, though it was too early to have the problem solved.In next 10 years, however, Zoellick said he could not imagine China continuing to rely on exports for growth, especially when developed economies have had difficulties recovering.By shifting away from an over-dependence on export-led growth to a greater reliance on domestic demand and investment, China could benefit not only itself but the world economy, he said.As China's 12th Five-Year Plan has pointed the way forward with what needs to be done, Zoellick said the ongoing research will try to help with the "how."He said the report will cover issues such as how China can complete its transition to a market economy; how to promote open innovation; how to advance green development; how to deliver equality of opportunity and social security to citizens; how to strengthen the fiscal system, and how China can become a responsible stakeholder in the international system.During his stay in China, Zoellick also visited the country's wasteland-turned-grain-producing-base in the northeast, including a farm, a rice mill, an agricultural research center and a modern agricultural machinery park, and learned about how this land transformation had affected local people's lives.As the world population is expected to hit 9 billion by 2050, Zoellick said the World Bank has been urging G-20 countries to prioritize food issues."China feeds 20 percent of the world's population with less than 10 percent of the world's agricultural land and less than six percent of its water, so China could make a significant contribution to global food security," Zoellick said.

BEIJING, July 5 (Xinhuanet) -- A black iPhone 4 prototype has appeared for sale on eBay and the highest bidding hit one million U.S. dollars as of Monday, according to media reports.The listing is set to expire on July 11.The seller "jtmaxo" said, "I am a licensed cell phone repairman, this iPhone was bought from a person who really didn't know who he had."The seller later was frustrated to find that it was unable to be activated via iTunes.According to a check through Apple’s database, it is indeed listed as a prototype, and it has the tester code "DF1692" etched in the bottom right corner.Different from the iPhone 4 sold on markets, the handset lacks the + and - on the volume buttons, although the screen is fully functional.The price for the prototype will not remain as high as it is as the seller said that several "non-legitimate" bids have already been deleted.